Northwire Canada EditionSaturday, October 17, 2026
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
M&A / Property

Rapid Dose Therapeutics Releases Nicotine Business Update and Extends Collaboration with International Nicotine Partner

DOSE · Price

Executive Summary

  • Rapid Dose Therapeutics extended its exclusive pre‑commercialisation and development agreement with an international nicotine partner for a further seven months, representing up to CAD 1.8 million in potential payments.
  • The company submitted Health Canada applications for NicStrip™ nicotine products (1–4 mg) and is conducting a GCP pharmacokinetic study to benchmark absorption against combustible cigarettes.
  • Two international PCT patent applications covering dissolvable and non‑dissolvable nicotine oral strip formats were filed in May 2025, expanding the firm’s IP portfolio.

Key Details

  • Agreement Extension: Retroactive effective date June 19 2025; term extended seven months from execution; total potential consideration up to CAD 1.8 million, subject to termination provisions.
  • Regulatory Progress: Health Canada submission filed August 4 2025 for NicStrip™ in 1 mg, 2 mg, 3 mg and 4 mg strengths.
  • Clinical Evaluation: Ongoing pharmacokinetic (PK) study launched June 2025 under Good Clinical Practice to compare nicotine absorption of NicStrip™ with combustible cigarettes.
  • Patent Activity: Two PCT applications filed May 2025 covering both dissolvable and non‑dissolvable nicotine oral strip formats.
  • Product Highlights:
  • Fast‑dissolving oral thin film delivering nicotine via the oral mucosa.
  • Customizable strengths (1–12 mg), flavors, dissolution profiles.
  • Discreet packaging, minimal waste, positive consumer feedback on flavor and mouthfeel.
  • Market Context:
  • Canadian nicotine pouch market valued at USD 112.2 M in 2024; projected CAGR 4.7% (2025‑2030).
  • Global nicotine pouch market projected to grow from USD 5.39 B (2024) to USD 25.40 B (2030), CAGR ≈29.6%.
  • Modern oral nicotine products category forecast to rise from USD 6.8 B (2024) to USD 75.7 B (2034), CAGR ≈27.7%.

Notable Quotes

  • “This extension marks an important milestone in advancing NicStrip™ toward potential commercialization discussions with our international nicotine partner.” – Mark Upsdell, CEO
  • “The financial commitment embedded in this extension underscores the shared seriousness in exploring a pathway to market in a rapidly evolving nicotine alternatives sector.” – Jason Lewis, Senior Vice President
Read the original news release →

More from Rapid Dose Therapeutics Corp.